Effects of an androgenic derivative on pre-established mammary tumours chemically induced in the rat

Summary The effects were studied of an androgenic derivative — danazol — administered at doses of 10–12 mg kg−1 day−1 during 97 days to rats with dimethylbenz[a] anthracene-induced mammary tumours. Our main observations were as follows. (a) Danazol did not influence ovarian function at the end of the assay. (b) The treatment with danazol reduced the incidence (P<0.05), number of tumours (P<0.05) and volume of malignant mammary tumours; on the other hand, the values of these parameters for benign tumours and those of doubtful expression were similar in both experimental groups. (c) Such differential action of Danazol seems to be due to the different incidence and/or content of receptors of both types of tumours. (d) The latter results lead to a hypothesis for the mechanism of action of danazol based on its behaviour at different levels. Similar content being viewed by others Abbreviations - RE: - oestradiol receptors - RP: - progesterone receptors References Barbieri RL, Canick JA, Makris A, Todd RB, Devies IJ, Ryan KJ (1977a) Danazol inhibits steroidogenesis. Fertil Steril 28:809–813 Barbieri RL, Canick JA, Ryan KJ (1977b) Danazol inhibits steroidogenesis in the rat testis in vitro. Endocrinology 101:1676–1682 Barbieri RL, Lee H, Ryan KJ (1979) Danazol binding to rat androgen, glucocorticoid, progesterone, and estrogen receptors: correlation with biologic activity. Fertil Steril 31:182–186 Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mama: suggestion for a new method of treatment, with illustrative cases. Lancet 2:104–107, 162–165 Blankenstein MA, Henkelman MS, Klijn GM (1985) Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. Eur J Clin Oncol 21:1493–1499 Brodovsky HS, Holroyde CP, Laucius JF, Dugery C, Serbin J (1987) Danazol in the treatment of women with metastatic breast cancer. Cancer Treat Rep 71:875–876 Chamness GC, Asch RH, Pauerstein CJ (1980) Danazol binding and translocation of steroid receptors. Am J Obstet Gynecol 136:426–429 Coombes RC, Perez D, Gazet JC (1983) Danazol treatment for advanced breast cancer. Cancer Chemother Pharmacol 10:194–195 Cooper AP (1836) The principles and practice of surgery. In: Cox (ed) London, vol 1, pp 333–335 Dmowski WP, Headly S, Radawnska E (1983) Effects of danazol on pulsatile gonadotropin patterns and on serum estradiol levels in normally cycling women. Fertil Steril 39:49–55 Elridge JC, Dmowski WP, Manesh VB (1974) Effects of castration of immature rats on serum FSH and LH and of various steroid treatments after castration. Biol Reprod 10:438–446 EORTC Breast Cancer Cooperative Group (1973) Standards for the assessment of estrogen receptors in human breast cancer. Eur J Cancer 9:379–381 Escrich E (1987a) Mammary cancer model induced by dimethylbenz[a]anthracene: a good experimental tool for the study of tumour markers. Int J Biol Markers 2:109–119 Escrich E (1987b) Validity of the DMBA-induced mammary cancer model for the study of human breast cancer. Int J Biol Markers 2:197–206 Escrich E, Prats M, Ferrer M, Casamitjana R, Gaya JM, Rivera F (1980) Determination of oestrogen receptors in human breast pathology: technical aspects and clinical significance. Pharmatherapeutica 2 [Suppl 2]: 102–107 Horwitz KB, McGuire WL (1975) Specific progesterone receptors in human breast cancer. Steroids 25:497–505 Huggins C, Grand LC, Brillantes FP (1961a) Mammary cancer induced by a single feeding of polynuclear hydrocarbons, and its suppression. Nature 189:204–207 Huggins C, Morii S, Grant LC (1961b) Mammary cancer induced by a single dose of polynuclear hydrocarbons: routes of administration. Ann Surg 154:315–318 Klijn JCM, Jong FH, Lamberst SWJ, Blankenstein MA (1985) LHRH-agonist treatment in clinical and experimental human breast cancer. J Steroid Biochem 23:867–873 Kokko E (1983) Progestin-like effects of danazol on rabbit uterus. Endocrinology 112:1110–1114 Lineweaver H, Burk D (1934) The determination of enzyme dissociation constants. J Am Chem Soc 56:658–666 Lowry OH, Rosebrough NJ, Farr LA, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275 Manni A, Santen R, Harvey H, Lipton A, Max D (1986) Treatment of breast cancer with gonadotropin-releasing hormone. Endocrine Rev 7:89–94 Manson AJ, Stonner FW, Neumann HC, Christiansen RG, Clarke RL, Ackerman JH, Page DF, Dean JW, Philipps DK, Potts GO, Beyler A'L, Clinton RO (1963) Steroidal heterocycles: VII. Androstano (2,3-d)isoxazoles and related compounds. J Med Chem 6:1–9 Mathe G, Keiling R, Vovan ML, Gastiaburu J, Prevot G, Vannetzel JM, Despax R, Jasmin C, Levi F, Musset M, Machover D, Misset JL (1986) Phase II trial of D-Trp-6-LH-RH in advanced breast cancer. Abstracts Int Symp Hormonal Manipulation of Cancer, Rotterdam Menon M, Azhar S, Menon KMJ (1980) Evidence that danazol inhibits gonadotropin-induced ovarian steroidogenesis at a point distal to gonadotropin-receptor interaction and adenosine 3′,5′ cyclic monophosphate formation. Am J Obstet Gynecol 136:524–530 Musich JR, Behrman SJ, Menon KMJ (1981) Estrogenic and antiestrogenic effects of danazol administration in studies of estraditol receptor binding. J Obstet Gynecol 140:62–69 Nicholson RI, Walker KJ, Turkes A, Dyas J, Plowman PN, Williams M, Blamley RW (1965) Endocrinological and clinical aspects of LHRH action (ICI 118630) in hormone dependent breast cancer. J Steroid Biochem 23:843–847 Peters TG, Lewis JD, Wilkinson EJ, Fuhrman TM (1977) Danazol therapy in hormone-sensitive mammary carcinoma. Cancer 40:2797–2800 Potts GO, Beyler AL, Schane HP (1974) Pituitary gonadotrophin inhibitory activity of danazol. Fertil Steril 25:367–372 Scatchard G (1949) The attractions of proteins for small molecules and ions. Ann N Y Acad Sci 51:660–672 Waxman JH, Harland SJ, Coombes RC, Wrigley PFM, Malpas JS, Powles T, Lister TA (1985) The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother Pharmacol 15:171–173 Williams MR, Walker KJ, Turkes A, Blarney RW, Nicholson RI (1986) The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53:629–636 Wood GP, Wu ChH, Flickinger GL, Mikhail G (1975) Hormonal changes associated with danazol therapy: Obstet Gynecol 45:302–304 Yen SSC (1983) Clinical applications of gonadotropine-releasing hormone and gonadotropin-releasing hormone analogs. Fertil Steril 39:257–266 Author information Authors and Affiliations Rights and permissions About this article Cite this article Escrich, E., Ribalta, T., Muntané, J. et al. Effects of an androgenic derivative on pre-established mammary tumours chemically induced in the rat. J Cancer Res Clin Oncol 117, 575–582 (1991). https://doi.org/10.1007/BF01613291 Received: Accepted: Issue date: DOI: https://doi.org/10.1007/BF01613291